Form 4: Kura Oncology CEO Buys Shares

Kura Oncology's CEO, Troy Wilson, recently purchased shares of the company's stock in multiple transactions.

Summary

• Troy Edward Wilson, President and CEO of Kura Oncology, Inc., purchased shares of common stock on August 12, 2025, and August 13, 2025.
• On August 12, 2025, Wilson acquired 36,506 shares at a weighted average price of $5.8505, in a range from $5.56 to $5.995.
• On August 13, 2025, Wilson acquired 13,494 shares at a weighted average price of $6.6417, in a range from $6.485 to $6.735.
• Following these transactions, Wilson directly owns 50,968 shares of common stock.
• Wilson also indirectly owns 279,194 shares through the One Fish Two Fish Revocable Trust and 300,000 shares through the Lorax Charitable Remainder Unitrust.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the CEO's stock purchases, which often signals confidence in the company's prospects.

Positives

• CEO Troy Wilson's purchase of Kura Oncology stock may signal confidence in the company's future prospects.
• The purchases increased Wilson's direct holdings to 50,968 shares.

Future Outlook

There are no explicit forward-looking statements in this filing.

Industry Context

Insider buying is often seen as a positive sign, suggesting that a company's leadership believes the stock is undervalued. However, it is only one factor among many to consider when evaluating a stock.

Stakeholder Impact

• Shareholders: The CEO's stock purchase may increase investor confidence.
• Employees: Positive sentiment could improve morale.

Key Dates

Recommendation

The CEO's purchase of shares indicates a strong belief in the company's future, suggesting a potential undervaluation and a positive outlook for investors.

Keywords

Kura Oncology, Troy Wilson, Insider Trading, Stock Purchase, SEC Form 4, KURA